Andrew Rice

Andrew is Professor of Pain Research at Imperial College London and Honorary Consultant in Pain Medicine at Chelsea and Westminster Hospital. He undertakes research and clinical practice in neuropathic pain, focussing on post herpetic neuralgia, peripheral nerve injury and HIV neuropathy.

Andrew received his medical degree from the St. Mary’s Hospital Medical School in 1982 and his research doctorate from the St. Thomas’ Hospital Medical School (UMDS) in 1991. He underwent his specialist clinical training mainly in Oxford and at St Thomas’ Hospital, London.

He is an author of more than 90 scientific publications, sits on the editorial boards of Pain and PLoS–Medicine and is lead editor of the four volume “Textbook of Clinical Pain Management”. He is currently Chair-elect (previously Secretary) of the International Association for the Study of Pain Special Interest Group on Neuropathic Pain (www.neupsig.org).

Andrew is Administrative Director of the Wellcome Trust funded London Pain Consortium (www.lpc.ac.uk) and the academic lead for the animal models work package on the EU Innovative Medicines Initiative grant “Europain”. He is also the link person between Europain and the corresponding US Food and Drugs Administration Critical Path Initiative: Analgesic Clinical Trial Innovations, Opportunities and Networks (ACTION).

He was the Michael Cousins lecturer at the Australian and New Zealand College of Anaesthetists (2009) and Covino Lecturer at Harvard University (2008).Andrew led the protocol development team for the Phase 2 clinical trial of EMA401 in post herpetic neuralgia patients and, given his clinical leadership in the area of neuropathic pain, helps guide the overall development of EMA401.

Andrew Rice is the Scientific Advisor at Spinifex Pharmaceuticals, based in Europe. With a background in Biotechnology, Andrew Rice has a rich history of leadership and innovation.Andrew Rice studied M.D. unknown at St. Mary's Hospital. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.